Importer of Controlled Substances Application: Andersonbrecon Inc. DBA PCI of Illinois, 32280 [2021-12819]
Download as PDF
<![CDATA[
32280
Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices
The company plans to bulk
manufacture small quantities of the
above controlled substances for use in
clinical research. No other activities for
these drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12817 Filed 6–16–21; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–853]
Importer of Controlled Substances
Application: Andersonbrecon Inc. DBA
PCI of Illinois
lotter on DSK11XQN23PROD with NOTICES1
18:41 Jun 16, 2021
Jkt 253001
7370
II
The company plans to import the
listed controlled substance for clinical
trial studies only. No other activity for
these drug codes is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of the Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
BILLING CODE 4410–09–P
Andersonbrecon Inc. DBA PCI
of Illinois has applied to be registered as
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 19, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 19, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021,
Andersonbrecon Inc. DBA PCI of
Illinois, 5775 Logistics Parkway,
Rockford, Illinois 61109–3608 applied
to be registered as an importer of the
following basic class(es) of controlled
substance(s):
VerDate Sep<11>2014
I
Tetrahydrocannabinols
Schedule
[FR Doc. 2021–12819 Filed 6–16–21; 8:45 am]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
SUMMARY:
Drug
code
Controlled substance
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Johnny C. Benjamin, Jr., M.D.;
Decision and Order
I. Procedural Background
On September 28, 2018, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause (hereinafter, OSC) to Johnny C.
Benjamin, Jr., M.D. (hereinafter,
Registrant) of Vero Beach, Florida. OSC,
at 1. The OSC proposed the revocation
of Registrant’s Certificate of Registration
No. BB3725732. Id. It alleged that
Registrant has ‘‘been convicted of a
felony relating to controlled substances
and ha[s] no state authority to handle
controlled substances.’’ Id. (citing 21
U.S.C. 824(a)(2) & (a)(3)).
Specifically, the OSC alleged that on
April 27, 2018, Registrant was convicted
by a Federal jury of: Conspiracy to
possess with intent to distribute furanyl
fentanyl resulting in death, in violation
of 21 U.S.C. 846; distribution of furanyl
fentanyl resulting in death, in violation
of 21 U.S.C. 841(a)(1); attempt to
possess with intent to distribute acetyl
fentanyl, in violation of 21 U.S.C. 846;
possession with intent to distribute
oxycodone, in violation of 21 U.S.C.
841(a)(1); and conspiracy to possess
with intent to distribute hydrocodone
and oxycodone, in violation of 21 U.S.C.
846. Id. at 2. The OSC alleged that on
July 6, 2018, the court issued its
Judgment and sentenced Registrant to
life in prison. Id. The OSC also alleged
that, on May 3, 2018, ‘‘the State of
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Florida Department of Health
immediately suspended Registrant’s
Florida Medical License.’’ Id. The OSC
further alleged that, as a result,
Registrant is ‘‘currently without
authority to handle controlled
substances in the State of Florida, the
state in which [Registrant] is registered
with the DEA.’’ Id. (citing 21 U.S.C.
824(a)(3); 21 CFR 1301.37(b)). The OSC
concluded that ‘‘DEA must revoke . . .
[Registrant’s] DEA registration based on
[his] lack of authority to handle
controlled substances in the State of
Florida.’’ OSC, at 2.
The OSC notified Registrant of the
right to request a hearing on the
allegations or to submit a written
statement, while waiving the right to a
hearing, the procedures for electing each
option, and the consequences for failing
to elect either option. Id. at 2–3 (citing
21 CFR 1301.43). The OSC also notified
Registrant of the opportunity to submit
a corrective action plan. OSC, at 3–4
(citing 21 U.S.C. 824(c)(2)(C)).
II. Adequacy of Service
In a sworn Declaration, dated January
17, 2019, a DEA Diversion Investigator
assigned to the West Palm Beach
District Office of the Miami Division
(hereinafter, DI) stated that she ‘‘spoke
by telephone with United States
Penitentiary Coleman SIS Technician
[T.B.] to determine what procedures the
prison had in place for serving legal
documents on prisoners and [to] make
arrangements for service of the [OSC] on
Registrant.’’ Government’s Request for
Final Agency Action (hereinafter,
RFAA) Exhibit (hereinafter, RFAAX) 7
(DI Declaration), at 1. DI stated that T.B.
explained that T.B. ‘‘would personally
serve the [OSC] on [Registrant].’’ Id.
Accordingly, DI stated that, on October
10, 2018, she sent the OSC via FedEx
addressed to T.B. along with an
unsigned Form DEA–12, Receipt for
Cash or Other items. Id. DI further
declared that on October 18, 2018, she
‘‘received a FedEx package . . . from
[T.B.] with the Form DEA–12 which had
been signed by Registrant and witnessed
by [T.B.], dated October 16, 2018.’’ Id.;
see also RFAAX 7, Attachment (Form
DEA–12).
Additionally, on September 28, 2018,
the DEA Office of Chief Counsel
(hereinafter, CC) mailed the OSC to
Registrant at both his registered address
and his prison address. RFAAX 6 (CC
Declaration of Service). Neither letter
was returned to the Office of Chief
Counsel as undeliverable. Id.
The Government forwarded its RFAA,
along with the evidentiary record, to
this office on January 23, 2019. In its
RFAA, the Government represents that
E:\FR\FM\17JNN1.SGM
17JNN1
]]>Agencies
[Federal Register Volume 86, Number 115 (Thursday, June 17, 2021)]
[Notices]
[Page 32280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12819]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-853]
Importer of Controlled Substances Application: Andersonbrecon
Inc. DBA PCI of Illinois
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Andersonbrecon Inc. DBA PCI of Illinois has applied to be
registered as an importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 19, 2021.
Such persons may also file a written request for a hearing on the
application on or before July 19, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021, Andersonbrecon Inc. DBA PCI of
Illinois, 5775 Logistics Parkway, Rockford, Illinois 61109-3608 applied
to be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols.................. 7370 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance for
clinical trial studies only. No other activity for these drug codes is
authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of the Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-12819 Filed 6-16-21; 8:45 am]
BILLING CODE 4410-09-P
